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Background: Total cholesterol (TC) concentration is the most commonly used measure of statin efficacy in the UK.
This study aimed to evaluate the effectiveness of statins in lowering TC, cardiovascular events (CV) and mortality
five common chronic diseases (chronic obstructive pulmonary disease (COPD), osteoarthritis (OA), rheumatoid
arthritis (RA), chronic kidney disease (CKD), and diabetes mellitus (DM)) and to compare effectiveness with the rest
of the population not recorded as having these diseases.
Methods: A population-based cohort study was conducted in Tayside population who had at least two TC
measurements between 1993 and 2007. There were 12,140 patients with chronic diseases and 9,481 patients in the
rest of the population not recorded as having these chronic diseases. The main outcomes were TC change from
baseline, CV events and all-cause mortality.
Results: Statin-associated TC reductions varied from 15% to 28% with baseline value of between 5.1 and 5.9 mmol/L
in the primary prevention (PP) and from 7% to 23% with baseline value of 4.5 to 5.2 mmol/L in the secondary
prevention (SP) among chronic diseases patients. In the rest of the population, TC reductions with statins were 31%
in PP and 28% in SP with baselines of 6.3 mmol/L and 5.3 mmol/L, respectively (test of heterogeneity with chronic
disease groups: p < 0.001). A notional reduction of 0.5 mmol/L in TC predicted variable reductions in incident CV
events of 30% in RA, 19% in CKD, and 20% in DM, and recurrent CV events by 62% in COPD, 16% in CKD, and 19% in
DM. The corresponding figures for the rest of population were 12% for incident CV events and 17% for the recurrent
CV events, respectively. Risk reductions for all-cause mortality varied from 20% to 36% in PP and from 18% to 40% in
SP, except in OA or RA patients in the chronic diseases and 11% in PP and 16% in the rest of population (test of
heterogeneity: p > 0.05).
Conclusions: The effectiveness of statins in common chronic diseases varied. With the exception of diabetes, statins
tends to be less effective in patients with the chronic diseases compared with the rest of the study population.
Changes in TC with statins appear not to correlate well with the changes in cardiovascular events and all-cause
mortality.
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Chronic disease now accounts for the majority of global
morbidity and mortality [1,2]. The prevalence of chronic
obstructive pulmonary disease (COPD) is 9-10% based on
spirometry testing [3] and is expected to be the fourth lead-
ing cause of death in the world by 2030 [4,5]. At least 2.8%
of the population (171 million) in the world suffer from dia-
betes mellitus (DM) in 2000 and this number is estimated
to double by 2030 [6]. Chronic kidney disease (CKD) affects
over 500 million people worldwide [7]. The prevalence of
CKD is 7.2% in those aged 30 years or older and varies from
23.4% to 35.8% in persons aged 64 years or older [8].
Rheumatoid arthritis (RA) has an estimated prevalence of
0.5–1.0% [9]. Osteoarthritis (OA) is the most common
form of arthritis and the leading cause of chronic disability
worldwide [10]. The prevalence of OA increases with age
and 12% of people over the age of 65 have symptomatic
knee OA [11]. In a significant proportion of patients with
these chronic diseases, statins would be indicated for the
prophylaxis of increased cardiovascular (CV) risk [12-21].
Certainly, dyslipidemia is associated with an increased CV
risk in patients with chronic diseases [22-24].
The ability of statins to reduce cardiovascular risk by
21% per mmol of low density lipoprotein cholersterol
(LDL-C) reduction was established in trial populations
[25]. However, in the UK, clinicians usually make treat-
ment decisions based on total cholesterol (TC), rather
than LDL cholesterol (although the latter can in certain
circumstances be calculated), sometimes using high
density lipoprotein concentration (HDL-C) measure-
ments as well. We have previously shown that TC re-
duction with lipid-lowering drugs predicts outcomes in
the statin trials almost as well as LDL-C and that TC
can be used as a reasonable measure of statin efficacy in
the absence of LDL-C [26,27]. We set out to compare
the effect of statins on total cholesterol-lowering, CV
events, and all-cause mortality in patients with five
chronic diseases (COPD, OA, RA, CKD, or DM) using
the rest of the population who had no record of having
these diseases as the referent group.
Methods
We performed a population-based longitudinal study
using the Medicines Monitoring (MEMO) unit record-
linkage database in Tayside, Scotland. This study was
approved by Tayside Research Ethics Committee and the
Tayside Caldicott Guardians. The study population con-
sisted of residents of Tayside who were registered with a
general practitioner between January 1993 and December
2007 and remained residents in Tayside or died during the
study period. Study subjects were the Tayside population
who had at least two different TC measurements sepa-
rated by at least 30 days of follow-up. They were divided
into chronic disease groups and the rest of the populationwho did not have these chronic diseases. The chronic dis-
ease groups included patients with a primary diagnosis of
COPD, OA, RA, CKD, or DM between 1993 and 2007.
COPD patients were identified from The Tayside Allergy
and Respiratory Disease Information system (TARDIS)
and Scottish Morbidity Record (SMR01) which are centra-
lised records of all Scottish hospital admission diagnoses;
OA or RA patients were identified from the regional Arth-
ritis dataset, SMR01, and patients with disease-modifying
anti-rheumatic drugs (DMARDs) use in the prescription
database; CKD patients were identified from SMR01 and
the regional biochemistry database (serum creatinine of
220 μmol/L or higher); DM patients were identified from
Diabetes Audit and Research in Tayside Scotland
(DARTS) database which is derived from the Scottish care
information diabetes collaboration (SCI-DC) [28]. SMR1
data were available from 1989 onward. The date of their
first diagnosis of each disease was used as the entry date
in chronic disease group. A frequency-matched calendar
year method was used to allocate an entry date for the rest
of the population. TC measurements were obtained from
the regional biochemistry database. Subjects were categor-
ized into statin-exposed and statin-unexposed groups
according to statin use status during the follow-up. Sub-
jects were also classified into primary prevention (PP) and
secondary prevention (SP) cohorts according to whether
they had established CV disease prior to the entry date.
The main outcomes were TC change calculated as TC
at the baseline minus TC at the end of follow up, the in-
cident (new) or recurrent Anti-platelet Trialist’s Collab-
oration (APTC) events of non-fatal myocardial
infarction (MI), non-fatal stroke, or vascular death, the
individual components of APTC, and all-cause mortality
during the follow-up. All-cause mortality data were
obtained from the General Register Office for Scotland.
Cox regression models with a time-dependent variable
of statins to avoid immoral time bias were employed to
assess the risk of APTC events or all-cause mortality
and adjusted for potential confounders including age,
gender, socioeconomic status, TC concentration change,
co-morbidities, and concurrent use of medications. Cox
model assumptions were checked prior to analysis. To
determine the presence of heterogeneity across different
study populations (different chronic diseases and the rest
of the population), the heterogeneity test (Cochrane's χ2
test (Q-statistics) was performed [29]. ‘Dose equivalents’
of simvastatin was used for other statin treatments in
order to calculate the mean daily dose. All analyses were
carried out using SAS version 9.1.
Results
Statins in chronic diseases
In total, 9,955 patients in the PP cohort (6,037 in the
statin-exposed group and 3,918 in the statin-unexposed
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statin-exposed group and 758 in the statin-unexposed
group). The PP cohort consisted of 1,274 COPD, 1,269
OA, 430 RA, 998 CKD, and 5,984 DM patients, in which
617 (48.4%), 696 (54.8%), 181 (42.1%), 442 (44.3%), and
4,101 (68.5%) were in the statin-exposed groups, respect-
ively. The SP cohort included 443 COPD, 247 OA, 78
RA, 704 CKD, and 713 DM patients, in which there
were 292 (65.9%), 175 (70.9%), 60 (76.9%), 386 (54.8%),
and 514 (72.1%) in the statin-exposed groups, respect-
ively. The mean follow-up years in PP were 3.08 in
COPD patients, 3.61 in OA patients, 3.90 in RA
patients, 3.61 in CKD patients, and 4.65 in DM patients
in the statin-exposed groups, and were 2.51, 2.69, 3.14,
2.51, and 3.50 in the statin-unexposed groups, respect-
ively. Correspondingly, the mean follow-up periods in
SP were 3.05, 2.88, 3.15, 2.92, and 4.32 in the statin-
exposed group, and were 2.26, 2.72, 2.72, 1.91, and 3.13
in the statin-unexposed groups.
Table 1 shows the baseline characteristics of subjects. TC
concentrations ranged from 5.11 mmol/L to 5.90 mmol/L
in PP and from 4.54 mmol/L to 5.20 mmol/L in SP
(P<0.001 between chronic diseases in both PP and SP).
Statin-associated TC reductions varied from 15% to 28% in
PP and from 7% to 23% in SP (Figure 1). Diabetic patients
had the most pronounced TC reduction with statins irre-
spective of PP or SP. TC changes in the statin-unexposed
groups were much lower than those in the statin-exposed
groups in both PP and SP (Figure 1).
The crude event rates per 1000 person-years (PYs) for
each outcome are shown in Additional file 1: Appendix 1.
CKD patients taking statins had the highest event rates for
most outcomes in both PP and SP. DM patients taking sta-
tins had the lowest event rates in PP and OA patients tak-
ing statins had the lowest event rates in SP.
Figure 2 shows the predicted proportional hazard ratio
for each outcome per notional 0.5 mmol/L statin-
associated TC reduction (in order to avoid negative
numbers, hazards ratios are given per 0.5 mmol/L TC
reduction). For the incident APTC events, 0.5 mmol/L
TC reduction with statins translated into 30% reduction
in RA patients, 20% in DM patients, and 19% in CKD
patients, but no effect in COPD or OA patients. For re-
current APTC events, a 0.5 mmol/L TC fall resulted in
62% reduction in COPD, 19% in DM, and 16% in CKD,
but no effect in OA or RA (Figure 3). Risk reduction in
incident non-fatal MI or incident non-fatal stroke was
observed in DM patients (both 18%), but was not seen
in other chronic disease patients. Risk of recurrent non-
fatal MI was reduced by 30% in CKD and 24% in DM.
Risk of recurrent non-fatal stroke was reduced by 35%
in CKD patient. Risk reduction of CV mortality was 37%
in OA, 20% in CKD, and 19% in DM in PP, and 65% in
COPD, 24% in CKD, and 25% in DM in SP (Additionalfile 1: Appendix 2). A 0.5 mmol/L TC reduction was
associated with reductions in all-cause mortality of
about 23% in COPD, 36% in OA, 31% in RA, 27% in
CKD, and 20% in DM in PP, and 40% in COPD, 26% in
CKD, and 18% in DM in SP (Figure 2).
Statins in the rest of the population
7,964 subjects (4,574 statin-exposed and 3,390 statin-un-
exposed) were included in PP with a mean follow up of
3.07 years in the statin-exposed group and 2.65 in the
statin-unexposed group and 1,517 subjects (1,315 statin-
exposed and 202 statin-unexposed) in SP with a mean
follow up of 2.89 and 2.37 years, respectively. Statin-
associated TC concentration fell by 31% from baseline of
6.03 mmol/L in PP and 28% from 5.28 mmol/L in SP
(Figure 1). Approximately 12% of TC reduction was also
observed in the statin-unexposed group.
The crude event rates per 1000 PYs were 14.8 (95%CI
12.9-16.9) for incident APTC events and 43.4 (95%CI
37.3-50.6) for recurrent APTC events in the statin-
exposed group. And the crude mortality rate were 12.2
(95%CI 10.5-14.2) in PP and 33.8 (95%CI 28.4-40.3) in
SP (Additional file 1: Appendix 1). Statin treatment
reduced APTC events, APTC components, or all-cause
mortality by approximately 12% in PP and by approxi-
mately 17% in SP per 0.5 mmol/L TC reduction (Figure 2
and Additional file 1: Appendix 2).
Comparison between chronic disease patients and the
rest of the population
Baseline TC concentrations in chronic disease patients
were lower than those in the rest of the population in
the statin-exposed groups (both PP and SP: P < 0.001).
Compared with chronic diseases patients, the mmol/L
fall of TC concentration and the percentage fall of TC
with statin use were larger in the remaining population
(both PP and SP: P < 0.001). The heterogeneity of the
proportional risk reduction in incident APTC events
(p < 0.01) and all-cause mortality in PP (p < 0.0001) per
0.5 mmol/L TC reduction was present across chronic
disease patients and the rest of the population, but not
in recurrent APTC events (p = 0.53), incident non-fatal
MI (p = 0.66), recurrent non-fatal MI (p = 0.39), incident
non-fatal stroke (p = 0.60), recurrent non-fatal stroke
(p = 0.10), CV mortality in PP (p = 0.16), CV mortality in
SP (p = 0.22), and all-cause mortality in SP (p = 0.12).
Discussion
We have examined the effectiveness of statins in chronic
disease patients compared with the remainder of the
population. With the exception of DM, statin-associated
TC reductions in chronic disease patients were in general
smaller than those in the rest of the population. Use of
statins was associated with improved survival in these
Table 1 Baseline characteristics in chronic diseases patients and the rest of the population
COPD n (%) OA n (%) RA n (%) CKD n (%) DM n (%) The rest of the population
n (%)
PP SP PP SP PP SP PP SP PP SP PP SP
Statin-exposed 617(48.4) 292(65.9) 696(54.8) 175(70.9) 181(42.1) 60(76.9) 442(44.3) 386(54.8) 4101(68.5) 514(72.1) 4574(57.4) 1315(86.6)
Age (years) (mean SD) 68.5(8.8) 70.2(9.0) 68.5(8.9) 70.8(9.6) 63.9(11.5) 68.1(9.9) 66.7(14.1) 73.6(10.5) 60.9(11.8) 67.3(10.5) 64.2(11.1) 67.1(10.9)
Male 297(48.1) 169(57.9) 295(42.5) 95(54.6) 46(25.4) 29(48.3) 248(56.4) 239(62.2) 2079(51.1) 323(63.0) 2182(47.7) 824(62.7)
Baseline TC (mmol/L)
(mean SD)
5.30(1.20) 4.68(1.10) 5.30(1.19) 4.54(1.07) 5.54(1.10) 4.95(1.28) 5.11(1.40) 4.85(1.44) 5.90(1.26) 5.20(1.36) 6.03(1.26) 5.28(1.13)
Simvastatin daily dose
(mg) (mean SD)
29(19) 29(20) 27(16) 35(27) 28(18) 33(25) 27(18) 26(17) 27(16) 30(24) 28(19) 30(22)
Social economic status
1 (most deprived) 285(46.1) 126(43.2) 141(20.3) 50(28.6) 46(25.4) 18(30.0) 108(25.2) 106(28.5) 1015(25.5) 125(24.9) 837(18.7) 322(25.1)
2-4 254(42.1) 130(45.2 402(58.9) 90(52.6) 100(56.8) 35(58.3) 244(56.9) 210(56.9) 2275(57.1) 310(61.6) 2681(59.8) 760(59.1)
5 (most affluent) 64(10.4) 31(10.6) 139(20.0) 31(17.7) 30(16.6) 7(11.7) 77(18.0) 56(15.1) 693(17.4) 68(13.5) 964(21.5) 203(15.8)
Concurrent use of drugs
Analgesics 453(73.4) 222(76.0) 591(84.9) 156(89.1) 153(84.5) 55(91.7) 303(68.6) 279(72.3) 2293(55.9) 335(65.2) 1897(41.5) 666(50.7)
Positive inotropic drugs 30(4.9) 49(16.8) 17(2.4) 6(3.4) 3(1.7) 7(11.7) 40(9.1) 89(23.1) 174(4.2) 76(14.8) 106(2.3) 62(4.7)
Diuretics 386(62.6) 183(62.7) 416(59.8) 100(57.1) 97(53.6) 39(65.0) 313(70.8) 311(80.6) 1932(47.1) 325(63.2) 2082(45.5) 569(43.3)
Beta-adrenoceptor
blocking drugs
97(15.7) 78(26.7) 290(41.7) 94(53.7) 57(31.5) 41(68.3) 204(46.2) 208(53.9) 1456(35.5) 299(58.2) 1816(39.7) 776(59.0)
Hypertension and
heart failure
373(60.5) 213(73.0) 431(61.9) 124(70.9) 82(45.3) 48(80.0) 303(68.6) 272(70.5) 2712(66.1) 390(75.9) 2135(46.7) 781(59.4)
Nitrates & calcium-channel
blockers
393(63.7) 235(80.5) 415(59.6) 130(74.3) 99(54.7) 51(85.0) 301(68.1) 302(78.2) 1951(47.6) 390(72.9) 2202(48.1) 947(72.0)
Anticoagulants 43(7.0) 49(16.8) 56(8.1) 13(7.4) 13(7.2) 13(21.7) 64(14.5) 104(26.9) 237(5.8) 103(20.0) 227(4.9) 97(7.4)
Antiplatelet drugs 400(64.8) 244(83.6) 423(60.8) 152(86.9) 93(51.4) 45(75.0) 242(54.8) 297(76.9) 2039(49.7) 421(81.9) 2329(50.9) 1107(84.2)
Corticosteroids 457(74.1) 210(71.9) 208(29.9) 46(26.3) 109(60.2) 32(53.3) 163(36.9) 127(32.9) 1093(26.7) 148(28.8) 942(20.6) 260(19.8)
NSAID drugs 180(29.2) 63(21.6) 342(49.1) 71(40.6) 110(60.8) 34(56.7) 91(20.6) 77(20.0) 1586(38.7) 166(32.3) 1292(28.3) 323(24.6)
Co-morbidity
Angina, TIA, heart failure 56(9.1) 142(48.6) 34(4.9) 17(9.7) 6(3.3) 9(15.0) 33(7.5) 140(36.3) 169(4.1) 109(21.2) 187(4.1) 508(38.6)
Diabetes mellitus 111(18.0) 33(11.3) 131(18.8) 14(8.0) 36(19.9) 11(18.3) 67(15.2) 60(15.5) - - - -
Sheng
et
al.BM
C
Public
H
ealth
2012,12:712
Page
4
of
9
http://w
w
w
.biom
edcentral.com
/1471-2458/12/712
05
10
15
20
25
30
35
C O PD O A R A CK D D M T he rem ain ing 
population
%
Statin-exposed Statin-unexposed
Primary prevention 
%
 T
C 
re
du
ct
io
n
C O P D O A R A CK D D M T h e rem a in ing 
population
0
5
10
15
20
25
30
35
%
Secondary prevention
Statin-exposed Statin-unexposed
%
 T
C 
re
du
ct
io
n
Figure 1 TC concentration changes in primary prevention and secondary prevention patients.
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http://www.biomedcentral.com/1471-2458/12/712chronic disease patients for the primary prevention of CV
events and in COPD, CKD, or DM patients for the sec-
ondary prevention of CV events. The risk reductions in
APTC events and all-cause mortality in PP were signifi-
cantly different across chronic disease patients and the
rest of the population, but were not heterogeneous in SP.
The majority of previous studies focused on LDL-C
concentration when evaluating the effect of statins in
disease population. In this study, total cholesterol rather
than LDL-C concentration was used to investigate the
effect of statins on cholesterol changes in different
chronic disease populations. There were several reasons:
firstly, in the UK clinicians usually make statin titration
decisions based on TC plus or minus HDL-C measure-
ments. Secondly, LDL-C can be measured from the
blood but it is expensive. So LDL-C is rarely measured
in clinical practice and is usually calculated instead. A
mathematical equation called Friedewald equation(LDL =TC-HDL-TG/2.17 (mmol/L) is used to calculate
LDL-C using values for total cholesterol, HDL-C and
TG. When calculating LDL-C with the equation, it
requires a fasting TG measurement [30]. Thirdly, in Tay-
side population there were approximately 15% of
patients (COPD, OA, RA, or CKD) with at least two
separate TC measurements and 35% in diabetic patients.
HDL-C concentration had similar measurements as TC
concentration in MEMO database. However, there were
very few TG measurements in these populations. This
resulted in a large number of missing records for calcu-
lating LDL-C concentration and the effect of statins on
LDL-C could not be investigated in this study.
In chronic disease patients exposed to statins, baseline
TC concentrations were lower than those in the rest of
the population. There are several possible explanations
for this. Firstly, the average age in the chronic disease
groups was higher than those in the rest of the
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Figure 2 The adjusted hazards ratios of APTC and all-cause mortality in primary and secondary prevention.
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tions decrease with age in older men and women
[31,32]. Secondly, the rest of the population group was
defined as population with at least two different TC
measurements. These people were more likely to have
other medical conditions such as hyperlipidmia, MI, and
possibly to have higher baseline TC than the general
population. So they were not completely representative
of the general population. Thirdly, decreased TC con-
centration is seen with chronic disease or inflammation
in the elderly [33-40]. Fourthly, low TC concentration is
found with malnutrition or poor health status in elderly
persons [33,35]. This appears to be related to lower
baseline TC in SP than in PP. Fifthly, it could be also
due to greater tendency of physicians to begin statins
therapy earlier in patients with several risk factors of CV
events. Finally, different mechanisms in chronic diseases
may lead to different baseline TC and different TC
reductions after statin therapy.
In addition, the impact of statins in chronic disease
patients was less than that in the general population.
One explanation was likely that the baseline TC concen-
trations did not reflect usual levels in these disease
populations. The timing of lipid estimations can affect
the results sometimes quite markedly. Cholesterol tests
include fasting and non-fasting (random) blood samples.
A recent study compared fasting and non-fasting TC
and HDL-C concentration in adults and found that there
were statistically significant differences between fastingand nonfasting results for total cholesterol, but no sig-
nificant difference between non-fasting HDL-C and fast-
ing HDL-C [41]. TC concentrations were slightly higher
in the non-fasting state, but fasting and non-fasting
values were highly correlated [41]. Therefore it is likely
that many of lipid collections were non-fasting and per-
formed during inter current illness, which result in dif-
ferent responses to statins in these chronic disease
patients. Although there was a difference in TC, it was
not clinically significant in diabetic or non-diabetic
patients [42].
Average daily doses of statins in chronic disease
groups were similar to those in the rest of the popula-
tion in both PP and in SP. This suggested that differen-
tial TC reductions with statin use across the disease
groups were not due to different statin doses. In second-
ary prevention there was no heterogeneity in the risk re-
duction across different study populations. This might
be because the data were sparse in some chronic diseases
with resulting low statistical power. In addition, the het-
erogeneous effects of standardized dose of simvastatin
may be affected by the type of lipid abnormality and het-
erogeneity in differing disease states. For example, dia-
betic dyslipidemia consists of low HDL-C concentrations,
increased TG concentrations, and postprandial lipemia,
which is not captured by a focus on TC concentration
[43]. In CKD patients, depressed HDL-C and increased
TG are the major lipid abnormalities and LDL-C
showed a ‘J-curve’ with respect to severity of disease
0%
10%
20%
30%
40%
50%
60%
70%
Primary prevention Second ary prevention
%
 A
PT
C 
ris
k 
re
du
ct
io
n 
pe
r 0
.5
 m
m
ol
/L
 T
C 
re
dc
ut
io
n
COPD OA RA CKD DM The remaining population
0%
10%
20%
30%
40%
50%
60%
70%
80%
Primary prevention   Secondary prevention
%
 A
PT
C 
ris
k 
re
du
ct
io
n 
pe
r 0
.5
 m
m
ol
/L
 T
C 
re
dc
ut
io
n
COPD OA RA CKD DM The remaining population
Figure 3 The proportional risk reduction of APTC events and all-cause mortality per 0.5 mmol/L TC concentration reduction.
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increased and LDL-C is not strongly correlated with
outcome in CKD [45].
Our study found that although there was less TC re-
duction with statins in some chronic disease groups than
those in the rest of population, more benefit on the risk
reduction of the outcomes was observed in some
chronic disease groups, perhaps reflecting differential
impacts of the pleiotropic anti-inflammatory effect of
statins in chronic diseases. For example, statins have
been suggested to have pleiotropic (anti-inflammatory)
effects in patients with inflammatory diseases such as
COPD and rheumatoid arthritis [46-48].
The beneficial effects of statins have been seen in clin-
ical trials and observational studies in COPD, RA, CKD
and diabetes [49-57]. Mancini et al reported that statin
use exhibited a reduced MI risk ratio (RR 0.48 95% CI
0.39-0.59) in COPD patients with coronary revasculari-
zation (high CV risk cohort) [49]. Daily use of 20 mg or
40 mg simvastatin was associated with the range from18% to 24% TC reduction and exhibited an improvement
in vascular function in RA patients [51-53]. A meta-
analysis that examined fifty RCTs and found that TC
concentration was significantly lower by 19% with statins
than with placebo in CKD patients with established
CVD [56]. A 21% risk reductions with lipid-lowering
drugs in both incident and recurrent major coronary
events in diabetic patients has been reported in another
meta-analysis [57]. TC concentration showed a decrease
of 15-20% in diabetic groups, which was a little smaller
than that in our findings. In general, although there were
some differences in the complexity of study design and
patients selection between these studies and ours, they
were in general agreements with our findings in patients
with COPD or CKD or diabetes mellitus.
This is the first population-based study to investigate
the comparative effectiveness of statins across chronic
diseases patients and the rest of the population.While
some randomized clinical trials provided the evidence of
statin efficacy in an ideal setting in these chronic disease
Sheng et al. BMC Public Health 2012, 12:712 Page 8 of 9
http://www.biomedcentral.com/1471-2458/12/712patients, our study assessed the effectiveness of statins
under usual care setting. The study by using healthcare
utilization databases has good external validity. In
addition, we took into account an extensive list of cov-
ariates in adjusting for potential confounders. However,
there are some limitations in our study. Our study may
be influenced by potential unmeasured or immeasurable
confounders such as cofounders related to the disease
inherent progress or some other confounders of smok-
ing status and alcohol consumption. We included the ef-
fect of statins on cholesterol lowering in five chronic
diseases, but we did not study other chronic diseases
such as chronic hepatitis, autoimmune diseases, etc. An-
other limitation of our study is the relatively small num-
ber of OA or RA patients with prior CV disease and
resulting limited statistical power to provide meaningful
results. We assumed if a patient dispensed his/her statin
prescription he/she would be adherent to the treatment.
However, we have no way of knowing true adherence.
Furthermore comparative effectiveness studies in larger
populations are required to confirm these relationships
(e.g. the Trial of Atorvastatin for the primary prevention
of cardiovascular events in patients with rheumatoid
arthritis (TRACE-RA)). Also the effects of statins were
not separately studied for men and women in our study.
Gender differences might help to explain differential
effects of statins in chronic diseases. Adherence and per-
sistence of statins might also affect the effectiveness of
statins and could vary between chronic diseases. Further
studies should also study individual statins, smoking sta-
tus, alcohol consumption, and other possible confoun-
ders in different populations.Conclusion
The cholesterol lowering effect of statins among chronic
diseases patients was generally less than that in the rest of
the study population and showed considerable heterogen-
eity. The proportional risk reduction in cardiovascular
events and all-cause mortality with statins per 0.5 mmol/L
TC reduction also varied across different chronic disease
groups compared with the rest of the population in PP,
but there was no heterogeneity in SP. There was also an
apparent disconnection between reductions in TC and
outcome benefits that warrants further study. For practis-
ing clinicians, there appears to be meaningful heterogen-
eity in the effectiveness of statins between different disease
groups which warrants further study.Additional file
Additional file 1: Appendix 1.The crude event rates for the outcomes
in chronic diseases patients and the rest of the population. Appendix 2.
The adjusted hazards ratios of outcomes with statin use in PP and SP.Competing interests
All authors declare: no support from any organisation for the submitted
work; no financial relationships with any organisations that might have an
interest in the submitted work in the previous 3 years; no other relationships
or activities that could appear to have influenced the submitted work.
Authors’ contribution
XS carried out the statistical analysis under the supervision of LW and wrote
the first draft of the paper. LW, MJM, TMM were involved in the design of
the study, interpretation of results and re-drafting of the paper. LW is
guarantor for this study. All authors read and approved the final manuscript.
Acknowledgement
None.
Author details
1Medicines Monitoring Unit, Division of Medical Sciences, Ninewells Hospital
& Medical School, University of Dundee, Dundee DD1 9SY, UK. 2Department
of Biochemical Medicine, Division of Clinical & Population Sciences &
Education, Ninewells Hospital & Medical School, University of Dundee,
Dundee DD1 9SY, UK.
Received: 9 December 2011 Accepted: 14 August 2012
Published: 30 August 2012
References
1. Yach D, Hawkes C, Gould CL, Hofman KJ: The global burden of chronic
diseases: Overcoming impediments to prevention and control. JAMA
2004, 291:2616–2622.
2. Beaglehole R, Yach D: Globalisation and the prevention and control of
non-communicable disease: The neglected chronic diseases of adults.
Lancet 2003, 362:903–908.
3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM: Global
burden of COPD: systematic review and meta-analysis. Eur Respir J 2006,
28:523–532.
4. Mathers CD, Loncar D: Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med 2006, 3:e442.
5. Murray CJL, Lopez AD: Alternative projections of mortality and disability
by cause 1990–2020: Global Burden of Disease Study. Lancet 1997,
349:1498–1504.
6. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes:
estimates for 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.
7. Couser WG, Shah S, Kopple J, Beerkens P, Wilson A, Feehally J, Reiser T,
Riella M: A call to action on World Kidney Day, 8 March 2007. Kidney Int
2007, 71:369–370.
8. Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in
population-based studies: systematic review. BMC Publ Health 2008, 8:117.
9. Silman AJ, Pearson JE: Epidemiology and genetics of rheumatoid arthritis.
Arthritis Res 2002, 4(Suppl 3):S265–S272.
10. Osteoarthritis: National clinical guideline for care and management in adults:
Royal College of Physicians; Available from: http://www.nice.org.uk/
nicemedia/pdf/CG059FullGuideline.pdf (accessed on 01/03/2011).
11. Brion PH, Kalunian KC: Oxford textbook of medicine. In Section 18.8.
Osteoarthritis. 4th edition. Edited by Warrell DA, Cox TM, Firth JD, Benz EJ Jr.
Oxford: Oxford University; 2003.
12. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W,
Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement
for healthcare professionals from the American Heart Association.
Circulation 1999, 100:1134–1146.
13. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from
coronary heart disease in subjects with type 2 diabetes and in
nondiabetic subjects with and without prior myocardial infarction. N
Engl J Med 1998, 339:229–234.
14. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL,
McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L,
Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of
cardiovascular disease: a statement from the American Heart Association
Councils on Kidney in Cardiovascular Disease, High Blood Pressure
Research, Clinical Cardiology, and Epidemiology and Prevention.
Circulation 2003, 108:2154–2169.
Sheng et al. BMC Public Health 2012, 12:712 Page 9 of 9
http://www.biomedcentral.com/1471-2458/12/71215. Perazella MA, Khan S: Increased mortality in chronic kidney disease: a call
to action. Am J Med Sci 2006, 331:150–153.
16. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD: COPD
and incident cardiovascular disease hospitalizations and mortality: Kaiser
Permanente Medical Care Program. Chest 2005, 128:2068–2075.
17. Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes
of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir
J 2008, 32:962–969.
18. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR: Cardiovascular morbidity
and mortality in patients with seropositive rheumatoid arthritis in
Northern Sweden. J Rheumatol 1997, 24:445–451.
19. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE:
Cardiovascular death in rheumatoid arthritis: a population-based study.
Arthritis Rheum 2005, 52:722–732.
20. Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: Role of
comorbidities. Eur Respir J 2006, 28:1245–1257.
21. Yerram P, Karuparthi PR, Hesemann L, Horst J, Whaley-Connell A: Chronic
kidney disease and cardiovascular risk. J Am Soc Hypertens 2007, 1:178–184.
22. Haffner SM: Management of dyslipidemia in adults with diabetes.
American Diabetes Association. Diabetes Care 1998, 21:179–182.
23. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A,
Bellanuova I, Malatino LS, Soldarini A: Hyperhomocysteinemia predicts
cardiovascular outcomes in hemodialysis patients. Kidney Int 2002,
61:609–614.
24. Hunninghake DB: Cardiovascular disease in chronic obstructive
pulmonary disease. Proc Am Thorac Soc 2005, 2:44–49.
25. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R,
Barnes EH, Keech A, Simes J, Collins R: Cholesterol Treatment Trialists’
(CTT) collaboration. Efficacy and safety of more intensive lowering of
LDL cholesterol: a meta-analysis of data from 170,000 participants in 26
randomised trials. Lancet 2010, 376:1670–1681.
26. Murphy MJ, Wei L, Watson AD, MacDonald TM: 'Real-life' reduction in
cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol 2008, 65:587–592.
27. Sheng X, Wei L, Murphy MJ, MacDonald TM: Statins and total (not LDL)
cholesterol concentration and outcome of myocardial infarction: results
from a meta-analysis and an observational study. Eur J Clin Pharmacol
2009, 65:1071–1080.
28. The Scottish Government: Scottish Diabetes Core Dataset.; . Available from:
http://www.scotland.gov.uk/Publications/2003/01/16290/17641. (accessed
on 30/03/2011).
29. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis.
Stat Med 2002, 21(11):1539–1558.
30. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem 1972, 18:499–502.
31. Ferrara A, Barrett-Connor E, Shan J: Total, LDL, and HDL cholesterol
decrease with age in older men and women. The Rancho Bernardo
Study 1984-1994. Circulation 1997, 96:37–43.
32. Abbott RD, Yano K, Hakim AA, Burchfiel CM, Sharp DS, Rodriguez BL, Curb JD:
Changes in total and high-density lipoprotein cholesterol over 10- and 20-
year periods (the Honolulu Heart Program). Am J Cardiol 1998, 82:172–178.
33. Manolio TA, Ettinger WH, Tracy RP, Kuller LH, Borhani NO, Lynch JC, Fried
LP: Epidemiology of low cholesterol levels in older adults. The
Cardiovascular Health Study. Circulation 1993, 87:728–737.
34. Schaefer EJ, Moussa PB, Wilson PW, McGee D, Dallal G, Castelli WP: Plasma
lipoproteins in healthy octogenarians: Lack of reduced high density
lipoprotein cholesterol levels: Results from the Framingham Heart Study.
Metabolism 1989, 38:293–296.
35. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-
inflammation complex syndrome in dialysis patients: causes and
consequences. Am J Kidney Dis 2003, 42:864–881.
36. Iribarren C, Jacobs DR Jr, Sidney S, Claxton AJ, Gross MD, Sadler M,
Blackburn H: Serum total cholesterol and risk of hospitalization, and
death from respiratory disease. Int J Epidemiol 1997, 26:1191–1202.
37. Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlén G: Lipoprotein (a), lipids,
and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis
1991, 50:366–368.
38. Dursunoğlu D, Evrengül H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, Kiliç
M: Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis:
serum levels and relationship to inflammation. Rheumatol Int 2005,
25:241–245.39. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe
NR, Klag MJ: Association between cholesterol level and mortality in
dialysis patients: Role of inflammation and malnutrition. JAMA 2004,
291:451–459.
40. Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of
follow-up from the Framingham study. JAMA 1987, 257:2176–2180.
41. Craig SR, Amin RV, Russell DW, Paradise NF: Blood cholesterol screening.
J Gen Intern Med 2000, 15:395–399.
42. Weiss R, Harder M, Rowe J: The relationship between nonfasting and
fasting lipid measurments in patients with or without type 2 diabetes
mellitus receiving treatment with 3-hydroxy-3methyglutaryl-coenzyme A
reductase inhibitors. Clin Ther 2003, 25:1490–1497.
43. American Diabetes Association: Management of dyslipidemia in adults
with diabetes. Diabetes Care 1998, 21(1):179–182.
44. Harper CR, Jacobson TA: Managing dyslipidemia in chronic kidney
disease. J Am Coll Cardiol 2008, 51(25):2375–2384.
45. Kaysen GA: Dyslipidemia in chronic kidney disease: causes and
consequences. Kidney Int 2006, 70:555–558.
46. Walsh GM: Statins as emerging treatments for asthma and chronic
obstructive pulmonary disease. Expert Rev Respir Med 2008, 2(3):329–335.
47. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell
HA, Sattar N: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-
blind, randomised placebo-controlled trial. Lancet 2004, 363(9426):2015–2021.
48. Paraskevas KI: Statin treatment for rheumatoid arthritis: a promising
novel indication. Clin Rheumatol 2008, 27(3):281–287.
49. Lee TM, Lin MS, Change NC: Usefulness of C-reactive protein and
interleukin-6 as predictors of outcomes in patients with chronic
obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008,
101:530–535.
50. van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Stam H,
Mertens FW, van Domburg RT, Poldermans D: Effect of statin therapy on
mortality in patients with peripheral arterial disease and comparison of
those with versus without associated chronic obstructive pulmonary
disease. Am J Cardiol 2008, 102(2):192–196.
51. Mäki-Petäjä KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM,
Wilkinson IB: Ezetimibe and simvastatin reduce inflammation, disease
activity, and aortic stiffness and improve endothelial function in
rheumatoid arthritis. J Am Coll Cardiol 2007, 50(9):852–858.
52. Hermann F, Forster A, Chenevard R, et al: Simvastatin improves
endothelial function in patients with Rheumatoid arthritis. J Am Coll
Cardiol 2005, 45:461–464.
53. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H, Tuzun C:
Effects of Angiotensin-converting enzyme inhibition and statin
treatment on inflammatory markers and endothelial functions in
patients with longterm rheumatoid arthritis. J Rheumatol 2005,
32(11):2095–2101.
54. Van Doornum S, McColl G, Wicks IP: Atorvastatin reduces arterial stiffness
in patients with rheumatoid arthritis. Ann Rheum Dis 2004,
63(12):1571–1575.
55. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman
AM, Paulus HE, Park GS, Gong T, Ansell BJ: Effects of high-dose
atorvastatin on antiinflammatory properties of high density lipoprotein
in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007,
34(7):1459–1464.
56. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F,
Nicolucci A, Craig JC: Effects of statins in patients with chronic kidney
disease: meta-analysis and meta-regression of randomised controlled
trials. BMJ 2008, 336(7645):645–651.
57. Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug
treatment for diabetic and non-diabetic patients: meta-analysis of
randomised controlled trials. BMJ 2006, 332(7550):1115–1124.
doi:10.1186/1471-2458-12-712
Cite this article as: Sheng et al.: The comparative effectiveness of statin
therapy in selected chronic diseases compared with the remaining
population. BMC Public Health 2012 12:712.
